公司状况 经济观察网锦好医疗(920925)在2026年有以下几方面事件值得关注。 业绩经营情况 公司于2026年2月9日发布2025年业绩快报，显示营业收入3.08亿元(同比增长65.26%)，净利润1515.78万 元(同比增长153.62%)。后续需关注正式年度报告的披露时间(通常为4月底前)，以获取详细财务数据及 业务分析。 2025年第四次临时股东会全票通过2026年银行授信额度议案，决议于2026年1月6日公告。后续需关注资 金实际投向是否支持业务扩张或技术升级。 业务进展情况 公司2024年收购Intricon听力健康业务后，助听器芯片销售收入在2025年实现约2000万元(同比增长显 著)。在全球老龄化背景下，美国OTC助听器需求持续增长，后续技术整合及全渠道运营效果可能成为 焦点。 以上内容基于公开资料整理，不构成投资建议。 2026年1月9日，公司发布员工持股计划草案，涉及48名核心骨干，锁定期14个月，业绩考核目标包括 2026年销售量或净利润增长率不低于12%。计划实施后，其进展及对公司团队稳定性的影响值得观察。 资金动向 ...

Core Viewpoint - The orthopedic industry is facing issues of high sales expenses and shrinking R&D investment, with major companies like Dabo Medical having sales expense ratios above the industry average [1] Group 1: Company Developments - Dabo Medical has recently made a new investment, fully acquiring Maikoste (Xiamen) Medical Equipment Co., Ltd. with a registered capital of 5 million yuan, focusing on professional technical services [1] Group 2: Stock Performance - Dabo Medical's stock price decreased from 50.14 yuan to 48.03 yuan over the past week, reflecting a decline of 2.66% and a volatility of 6.49%; on February 11, the stock fell by 1.58% with a net outflow of 10.377 million yuan [2] - As of February 12, the stock price slightly increased by 0.36% to 48.03 yuan, with a turnover rate of 0.60% and a trading volume of 82.96 million yuan; technical indicators suggest a downward trend [2] Group 3: Financial Performance - Dabo Medical expects a net profit attributable to shareholders for the year 2025 to be between 580 million yuan and 610 million yuan, representing a year-on-year growth of 62.55% to 70.96%; the non-recurring net profit is projected to grow by 59.42% to 69.93% [3] - The primary drivers of this growth are focused on core business, product innovation, and the advancement of international strategies, with a revenue of 1.876 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 22.69% [3] Group 4: Institutional Insights - Institutions predict a net profit growth rate of 50.67% for 2025, with a slowdown to 16.88% in 2026; current institutional ratings are neutral, and the fund holding ratio is low at 0.88%, indicating moderate market attention [4]

Company Overview - The closing price of Aojing Medical (688613.SH) on February 12, 2026, was 23.98 yuan, with a daily decline of 3.54% and a trading volume of 1.10 billion yuan, indicating a turnover rate of 3.31% [1] - As of February 12, the company's price-to-earnings ratio (TTM) was -910.15 times, and the price-to-book ratio was 2.29 times. The revenue forecast for 2025 is 224 million yuan, with a net profit attributable to the parent company of 13.53 million yuan, although the non-recurring net profit is expected to be a loss of 510,000 yuan [3] Industry Analysis - The medical device sector has seen a cumulative decline of 5.39% over the past 20 days, reflecting overall weak performance. Concerns regarding the continuity of medical procurement policies and increased risk aversion ahead of the long holiday have put pressure on small and medium-sized pharmaceutical stocks [4] Market Activity - On February 10, the stock price surged by 5.13% to 25.41 yuan, reaching a new high for the period. The subsequent decline on February 12 is viewed as a technical correction following a significant short-term increase [5] - The financing activity showed a recent trend of increased activity followed by a decline, with a net buy of 9.29 million yuan on February 10, but a net outflow of 7.63 million yuan on February 11, leading to a financing balance of 227 million yuan on February 12. The net outflow of main funds on February 12 indicates a profit-taking pressure from retail investors, who accounted for 38% of the inflow [2]

公司状况 2026年1月10日：董事会审议通过《关于使用闲置募集资金进行现金管理的议案》，计划使用不超过 1000万元闲置募集资金购买期限不超过6个月的低风险理财产品，旨在提高资金使用效率。 资金动向 经济观察网辰光医疗近期事件主要集中在2026年1月，涉及股东减持、公司治理变动及财务表现等方 面。 高管变动 2026年1月12日：公司公告显示，股东田丽芬于2025年11月13日至2026年1月9日期间通过集中竞价减持 15.65万股，持股比例由5.7139%降至5.5316%。其与一致行动人上海复孵科技有限公司合计持股比例由 8.1823%降至8.0000%，触及权益变动披露阈值。 业绩经营情况 2026年1月29日：公司披露2025年度业绩预告，预计归母净利润亏损5300万元至6600万元(上年同期亏损 6090万元)。业绩变动主要受磁共振系统行业竞争加剧影响，1.5T产品销售收入下滑，且7.0T科研用产 品未实现销售。 以上内容基于公开资料整理，不构成投资建议。 2026年1月26日：辰光医疗获融资买入35.76万元，融资净买入35.76万元，融资余额达1734.95万元，占 流通市值的1.28%，处于 ...

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a slight decline compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, with fluctuations influenced by the weak performance of small-cap stocks[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, highlighting a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating a relatively high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative tier and basic tier seeing transaction amounts drop by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which may lead to further declines in the North 50 Index[42]

通过天眼查大数据分析，椎元医学技术（上海）有限公司知识产权方面有商标信息13条，专利信息11 条，此外企业还拥有行政许可1个。 天眼查信息显示，椎元医学技术（上海）有限公司的股东为：上海赛立维生物科技有限公司、上海强基 企业管理合伙企业（有限合伙）、上海凯利泰医疗科技股份有限公司、杭州泽悦子宁创业投资合伙企业 （有限合伙）、上海张科禾苗创业投资合伙企业（有限合伙）。 来源：市场资讯 2月12日，天眼查融资历程显示，椎元医学技术（上海）有限公司近日获得"A轮"融资，涉及融资金额 2000万人民币，投资机构为三友医疗。 资料显示，椎元医学技术（上海）有限公司法定代表人为范明，成立于2021年，位于上海市，是一家以 从事研究和试验发展为主的企业。企业注册资本523.5102万人民币，并已于2026年完成了A轮，交易金 额2000万人民币。 ...

Group 1 - The core viewpoint of the news is that Lepu Medical (300003) is expected to see a significant increase in net profit in 2025, driven by a recovery in traditional business and breakthroughs in the medical aesthetics sector [1][2] - The company forecasts a net profit of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95%, ending a previous trend of decline [1] - The medical aesthetics business, particularly the Tongyan needle product, has rapidly gained traction since its launch in August 2025, generating approximately 100 million yuan in revenue by October 2025 [1] Group 2 - The financial report indicates that the growth in net profit is primarily due to the stabilization of traditional business and contributions from emerging sectors, with core cardiovascular intervention revenue showing steady growth [2] - The retail channel inventory for the pharmaceutical segment has been cleared, leading to double-digit growth in formulation revenue, while innovative drugs and medical aesthetics have become new sources of revenue [2] - The company expects a nearly 95% increase in net cash flow from operating activities, with a stable debt-to-asset ratio of 31%, indicating a solid financial position [2] Group 3 - Recently, Lepu Medical's stock price has shown limited volatility, closing at 17.98 yuan on February 11, 2026, with a slight decline of 0.17% on that day [3] - Over a 5-day period, the stock has seen a minor increase of 0.11%, but a notable decline of 11.38% over 20 days indicates short-term fluctuations [3] - The stock is positioned near the lower band of the Bollinger Bands, with weak MACD indicators, although the 60-day moving average provides support [3]

| 北证日均成交额环比继续下降，北证 50 | | --- | | 指数当周震荡显著 | ——北交所周报（2026 年 2 月第 1 周） 本报告导读： 2 月第 1 周 A 股市场缩量震荡，小盘股表现稍弱，北证 50 指数波动明显，单周小幅 下跌 0.70%，日均成交额回落至 200 亿元附近。当周北交所 2 只新股招股，无新股 上市。 次新板块持续回调，科创板年内首只未盈利新股 上市 2026.02.10 新股精要—动力电池热失控防护零部件领先提供 商固德电材 2026.02.10 IPO 月度数据一览（2026 年 1 月） 2026.02.03 次新板块回调明显，恒运昌申购收益亮眼 2026.02.02 北证交易活跃度回升，北证 50 指数回调 2026.02.01 证 券 研 究 报 告 投资要点： 新股研究 /[Table_Date] 2026.02.12 | [Table_Authors] | 王政之(分析师) | | --- | --- | | | 021-38674944 | | | wangzhengzhi@gtht.com | | 登记编号 | S0880517060002 | | | ...

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. is the first innovative medical device company to be accepted for IPO under the fifth set of listing standards of the Sci-Tech Innovation Board, aiming to raise 1.217 billion yuan for various projects, including R&D and marketing network development [1][6] Group 1: Company Overview - Core Medical is a leader in China's artificial heart industry, holding multiple "first" titles [4] - The company has several products included in China's special review process for innovative medical devices, leading the field in terms of the number of products [5] - The Corheart 6, the world's smallest and lightest commercialized magnetic levitation implantable artificial heart, was approved for market in June 2023, with a projected market share of over 45% in 2024 [5] Group 2: Financial Performance - The company reported revenues of 16.55 million yuan, 93.69 million yuan, and 70.48 million yuan for the years 2023, 2024, and the first half of 2025, respectively, with net losses of 170 million yuan, 132 million yuan, and 72.75 million yuan during the same periods [8] - Cumulative losses since 2022 have exceeded 500 million yuan [8] - Gross margins for the reporting periods were 66.25%, 69.66%, and 72.09%, consistent with industry averages [9] Group 3: Investment and Financing - Prior to the IPO, Core Medical attracted investments from several prominent institutions, including Hillhouse Capital and Zhengxin Valley Investment [2][14] - The company completed a D-round financing of over 100 million USD in April 2025, marking the largest market-based financing in China's innovative medical device sector for that year [16]

Core Viewpoint - The article emphasizes the importance of ensuring the safety of pharmaceuticals and medical devices during the winter season through a regulatory initiative in Xinjiang Shawan City, aimed at protecting public health [1] Group 1: Regulatory Actions - The Xinjiang Shawan City Market Supervision Administration is conducting a "100-day rectification action" focused on the quality and safety of pharmaceuticals and medical devices during winter [1] - The initiative targets pharmaceutical and medical device businesses, verifying the validity of operating licenses, legality of procurement channels, compliance in storage and maintenance, and completeness of incoming inspection [1] Group 2: Focus Areas - Key areas of focus include cold-chain pharmaceuticals, traditional Chinese medicine pieces, and commonly used medical devices [1] - The enforcement personnel are combining law enforcement with service, providing on-site guidance for businesses to standardize management and assisting with license changes [1] Group 3: Future Plans - The Xinjiang Shawan City Market Supervision Administration plans to continue enhancing precise regulation and warm service to further advance the "100-day rectification action" for pharmaceutical and medical device quality and safety [1] - The initiative aims to reinforce the primary responsibility of enterprises, ensuring that the public can use medications and medical devices with greater confidence during the winter [1]